Bertrand Georges
Hoofd Techniek/Wetenschap/O&O bij ALTIMMUNE, INC.
Profiel
Bertrand Georges is the founder of Altimmune UK Ltd., which was founded in 1992.
He held the title of Chief Technical Officer from 2004 to 2015.
Currently, Dr. Georges is the Chief Technology Officer at Altimmune, Inc. since 2015.
In the past, he worked as the Head-Immunology at Sedac Therapeutics SA from 1999 to 2003.
Dr. Georges obtained a doctorate degree from the Pasteur Institute of Iran.
Actieve functies van Bertrand Georges
| Bedrijven | Functie | Begin |
|---|---|---|
| ALTIMMUNE, INC. | Hoofd Techniek/Wetenschap/O&O | 01-03-2015 |
Eerdere bekende functies van Bertrand Georges
| Bedrijven | Functie | Einde |
|---|---|---|
Altimmune UK Ltd.
 Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Oprichter | 01-03-2015 |
Sedac Therapeutics SA
 Sedac Therapeutics SA Medical/Nursing ServicesHealth Services Sedac Therapeutics SA develops new peptide formulas synthetic products in the fields of diagnosis and vaccine immunotherapy. The company is headquartered in Lyon, France. | Corporate Officer/Principal | 01-01-2003 |
Opleiding van Bertrand Georges
| Pasteur Institute of Iran | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ALTIMMUNE, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Altimmune UK Ltd.
Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Health Technology |
Sedac Therapeutics SA
Sedac Therapeutics SA Medical/Nursing ServicesHealth Services Sedac Therapeutics SA develops new peptide formulas synthetic products in the fields of diagnosis and vaccine immunotherapy. The company is headquartered in Lyon, France. | Health Services |
